Why the study?
Multi-targeted tyrosine kinase inhibitors targeting tumor angiogenesis are increasingly approved for cancer treatment, but their cardiac side effects remain an ongoing clinical management challenge.
What are the mechanisms of cardiotoxicity associated with angiogenesis-targeting TKIs and how should cardiovascular risks be managed in cancer patients?
Design
Literature review
Authors
Loading...
Cardiac toxicities of approved multi-targeted TKIs warrant ongoing vigilance in oncology practice; extends prior reviews but leaves optimal monitoring strategies open.
What are the mechanisms of cardiotoxicity associated with angiogenesis-targeting TKIs and how should cardiovascular risks be managed in cancer patients?
This review highlights the critical need for cardio-oncology collaboration and baseline cardiovascular risk stratification in cancer patients treated with angiogenesis-targeting TKIs to manage cardiotoxicity.
Galvano et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: